Marginal zone lymphoma: old, new, targeted, and epigenetic therapies
نویسندگان
چکیده
منابع مشابه
Splenic marginal zone lymphoma.
Splenic marginal zone lymphoma (SMZL) is a specific low-grade small B-cell lymphoma that is incorporated in the World Health Organization classification. Characteristic features are splenomegaly, moderate lymphocytosis with villous morphology, intrasinusoidal pattern of involvement of various organs, especially bone marrow, and relative indolent course. Tumor progression with increase of blasti...
متن کاملRadiotherapy in marginal zone lymphoma
PURPOSE To evaluate the efficacy of radiotherapy (RT) for early-stage nodal and extranodal marginal zone lymphoma (MZL). MATERIALS AND METHODS Patients with stage I (n = 22) and stage II (n = 8) MZL, who were treated with RT were reviewed. The primary tumor localisation was in the orbita (n = 12), stomach (n = 8), head and neck other than the orbita (n = 8), breast (n = 1) and one case of mar...
متن کاملMarginal Zone B-cell lymphoma
Extra-nodal MZBCL of MALT type (7% of all NHL) is an indolent disease involving most often the stomach, where it usually follows chronic gastritis due to Helicobacter pylori (HP) infection. The disease may also localize in the lung, the thyroid, the salivary gland, the orbit. Splenic MZBCL (1% of all NHL on histologic samples) usually, though not invariably, presents splenomegaly associated cir...
متن کاملTargeted Therapies in Breast Cancer: New Approaches and Old Challenges.
proaches interacting with growth factor signaling pathways that lead to estrogen receptor activation. Currently, we are experiencing relevant progress in endocrine therapy through approaches interacting with these signaling pathways, and several compounds will become available for clinical use within the next years. However, despite the fact that several compounds which target mTOR, PI3K, or CD...
متن کاملOld medications and new targeted therapies in systemic sclerosis.
SSc is a multiorgan disease with significant morbidity that is associated with poor health-related quality of life. Treatment of this condition is often organ based and non-curative. However, there are newer, potentially disease-modifying therapies available to treat certain aspects of the disease. This review focuses on old and new therapies in the management of SSc in clinical practice.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Therapeutic Advances in Hematology
سال: 2012
ISSN: 2040-6207,2040-6215
DOI: 10.1177/2040620712453595